LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
19 January 2018 07:00 GMT LYNPARZA RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with